Nutritional considerations for glucagon-like peptide-based therapies: An Asian Indian consensus recommendation.
Most nutritional support statements for GLP-based therapies reached expert consensus.
Nutritional considerations for glucagon-like peptide-based therapies: An Asian Indian consensus recommendation.
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonists, collectively called GLP-based therapies (GLP-based therapies), cause gastrointestinal adverse effects and alter dietary intake, leading to nutritional deficiencies and loss of muscle mass and bone density.
This was a consensus-based study using a modified Delphi method with expert panel inputs informed by a literature review.
After the discontinuation of GLP-based therapies, sustained nutritional support may help prevent metabolic rebound.
There is a need for structured nutritional support for individuals on GLP-based therapies, especially for Asian Indians, considering their dietary pattern and increased risk of sarcopenia.
Implementing culturally driven nutritional recommendations, including diabetes-specific nutritional formula as an adjunct along with lifestyle modifications, can support optimizing long-term patient-centric outcomes.
The effectiveness and safety of GLP-based therapies, along with newly emerging nutrient-stimulating hormone (nutrient-stimulating hormone) based therapies, should be evaluated in long-term follow-up studies.